FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 546 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Pattern of DNA Damage Links Colorectal Cancer and Diet High in... July 22, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab February 26, 2021 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... October 1, 2020 College Student Rescues Cats Between Classes, Working 2 Jobs, And Planning... November 5, 2021 Load more HOT NEWS Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... EMA Recommends Granting a Marketing Authorisation for Duvelisib Girls Aloud members to join forces to raise money in Sarah... Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals...
